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Abstract
Objectives: Right posterior sectorectomy (RPS) preserves liver volume but typically requires a longer
parenchymal transection distance than does right hepatectomy (RH). This study was conducted to define
the advantages of one approach over the other.
Methods: Databases at two institutions were retrospectively reviewed for all patients submitted to RPS
or RH between January 2000 and August 2012. Primary outcomes were perioperative complications and
90-day mortality.
Results: Patients undergoing RPS (n = 100) and RH (n = 480), respectively, were similar in demograph-
ics, comorbidities, operative indications and Model for End-stage Liver Disease (MELD) mean scores (7.8
in the RPS group and 7.7 in the RH group; P = 0.49). A comparison of the RPS group with the RH group
showed no significant differences in mean estimated blood loss (697 ml versus 713 ml; P = 0.900), rate
of transfusions (19.2% versus 17.1%; P = 0.720), margin-positive resection (9.2% versus 11.6%; P =
0.70), complications (41.8% versus 42.0%; P = 1.000), bile leak (3.0% versus 4.0%; P = 1.000), or length
of stay (7.5 days versus 8.3 days; P = 0.360). Postoperative hepatic insufficiency (defined as a postop-
erative bilirubin level of >7 mg/dl or significant ascites), occurred less frequently after RPS (1.0% versus
8.5%; P = 0.005). Operation type remained an independent determinant of postoperative hepatic insuf-
ficiency after controlling for preoperative risk factors (RH: hazard ratio = 9.628, 95% confidence interval
1.295–71.573; P = 0.027). A total of 28 (4.8%) patients died within 90 days; these included 25 (5.2%)
patients in the RH group and three (3.0%) in the RPS group (P = 0.449).
Conclusions: Despite similar blood loss and overall morbidity, RPS is associated with less hepatic
insufficiency than RH. Right posterior sectorectomy is parenchyma-sparing and should be strongly
considered when it is technically feasible and oncologically sound.
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Introduction
Improvements in patient selection, surgical technique and peri-
operative care have led to the increased use of partial hepatectomy
for both benign and malignant indications with acceptable mor-
bidity and mortality.1,2 Partial hepatectomy is used in the manage-
ment of patients with primary hepatic tumours and those with
limited hepatic metastases with appropriate disease biology.3,4
Hepatic resection for metastatic disease is most frequently
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performed in patients with colorectal5–7 and neuroendocrine8
malignancies, but has also been reported in patients with metas-
tases from breast cancer,9,10 gastrointestinal stromal tumours,11
ovarian cancer,12 renal cell carcinoma13 and other malignancies.4,14
In the current era of modern chemotherapeutic and targeted
molecular agents, patients with metastatic disease who historically
would never have been considered appropriate for PH are now
potential candidates.6–8,15 Some may even benefit from repeat
hepatectomy in the face of second and third recurrences4,6,16,17 and
thus the preservation of liver parenchyma at the time of first
resection is valuable. Over the past three decades enhanced
understanding of hepatic anatomy and the use of intraoperative
ultrasound have resulted in the increased use of parenchyma-
preserving segmental resections,1 with a subsequent decrease in
formal lobar resection in some series.16 For lesions located in the
posterior sector (segments VI and VII), either formal right hepa-
tectomy (RH) or segmentally based right posterior sectorectomy
(RPS, also characterized as right posterior sectionectomy18) may
be performed.
Right posterior sectorectomy preserves functional parenchyma,
but requires the same mobilization as RH, often with division of
the right hepatic veins,14,19 and a longer parenchymal transection
line than RH (Fig. 1a–c). Isolation of the right posterior pedicle
typically requires intraoperative ultrasound guidance (Fig. 2).20
The advantages and disadvantages of RPS compared with a more
traditional RH approach are not well documented. This dual-
institution retrospective study was conducted to compare periop-
erative outcomes in patients undergoing, respectively, RPS and
RH.
Materials and methods
Hepatobiliary resection databases at two institutions (Emory
University, Atlanta, GA, USA and Johns Hopkins University, Bal-
timore, MD, USA) were queried for all patients aged 18 years
and submitted to either RPS or RH between January 2000 and
August 2012. Brisbane terminology was used to describe hepatic











Figure 1 Intraoperative photographs demonstrating right posterior sectorectomy (RPS). (a) Control of the right posterior pedicle, showing the
right posterior hepatic artery stump (silk tie, **), the right posterior portal vein stump (clip, *), the tumour in the right posterior sector (single
arrow), and the cystic duct stump (double arrow). (b) The plane of transection during RPS between segments V/VIII and VI/VII; the blue line
marks the plane for a right hepatectomy between segments V/VIII and IV. (c) The remnant liver after RPS; the blue line demonstrates the
difference in parenchymal volume between an RPS and a formal right hepatectomy
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sectorectomy’, ‘right posterior sectionectomy’ and ‘right lateral
sectionectomy’ are equivalent terms used to describe the ana-
tomic resection of segments VI and VII with ligation of the pos-
terior branch of the right portal pedicle, with or without division
of the right hepatic vein(s). ‘Right posterior sectorectomy’ (RPS)
will be used throughout this manuscript. Right hepatectomy was
defined as the resection of anatomic segments V–VIII with or
without caudate lobectomy.22 Patients who required ligation of
the middle hepatic vein were included only if the transection
plane paralleled the vein and segment IV was spared. Patients
who required extended RH or anatomic resection of adjacent
segments that would alter the defining hepatic procedure were
excluded. Patients who required additional minor hepatic proce-
dures (i.e. wedge resection, segmentectomy, radiofrequency or
microwave ablation) or additional non-hepatic resections (i.e.
bowel resection, hernia repair) were included. Adhesiolysis,
cholecystectomy and wedge biopsy, when performed in conjunc-
tion with either RPS or RH, were not considered as additional
procedures. A retrospective chart review was performed for clin-
icopathologic characteristics, perioperative details, short-term
outcomes and perioperative mortality. Smoking history and
alcohol abuse were determined from documentation in the
admission history and physical or clinic notes of the attending
physician. The presence of preoperative ascites was determined
by clinical evaluation or the presence of fluid consistent with
ascites on cross-sectional imaging. Preoperative laboratory values
were determined from laboratory reports within 30 days of
surgery; when multiple laboratory findings were available, the
values closest to the date of surgery were recorded. Model for
End-stage Liver Disease (MELD) scores and Child–Pugh class
were calculated accordingly. Postoperative hepatic insufficiency
(HI) was defined as postoperative peak bilirubin of >7 mg/dl23 or
the development of postoperative ascites24 as determined by a
postoperative drain output that exceeded 500 ml in a 24-h period
or the documentation in the medical record of significant ascites
requiring intervention. Complications were graded according to
the Clavien–Dindo system of classification;25 complications of
Grades III–V were considered to indicate major morbidity. Peri-
operative mortality was defined as death within 90 days of
surgery or during the same hospitalization. Overall survival was
defined as the time elapsed between the date of surgery and the
date of last contact or death.
Permission for the study was obtained prior to data collection
from the institutional review board at each institution. All data
were maintained in a manner compliant with the Health Insur-
ance Portability and Accountability Act of 1996.
Specific technique
Resections were performed under low central venous pressure
general anaesthesia, usually with the patient in the Trendelenburg
position. Details of the open14,20,22,26,27 and laparoscopic28–30 tech-
nique have been thoroughly described elsewhere. For open resec-
tions, a vertical upper midline incision or a subcostal incision with
or without extension to a vertical midline laparotomy was per-
formed according to the surgeon’s preference. Intraoperative
ultrasound was used at the discretion of the operating surgeon to
define anatomy and make a staging evaluation. Both RPS and RH
required the full mobilization of the right hemiliver. A Pringle
manoeuvre was used at the discretion of the surgeon. In most
resections, vascular control of the corresponding inflow and
outflow structures was obtained prior to parenchymal transec-
tion; in RPS temporary occlusion of the right posterior sector
pedicle was often used to demarcate the parenchyma. After the
anatomy had been established, the hepatic parenchyma was
divided using either the traditional clamp-crush technique or one
of several energy-assisted devices or staplers. Haemostatic agents
were used at the discretion of the surgeon. Postoperatively,
patients were admitted to either the intensive care unit or the
surgical floor as mandated by their condition.
(a) (b)
Figure 2 Intraoperative ultrasound during right posterior sectorectomy. (a) The right posterior portal pedicle (*) is in close proximity to the
tumour (arrow). (b) Colour Doppler imaging demonstrates loss of flow in the right posterior pedicle (*) after ligation (Fig. 1a), whereas flow
is apparent in the right anterior pedicle (**)
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Statistical analysis
Data were analysed using IBM spss Statistics forWindowsVersion
20.0 (IBM Corp., Armonk, NY, USA). Continuous variables were
compared using Student’s t-test. Categorical variables were com-
pared using Pearson’s chi-squared and Fisher’s exact tests, as
appropriate. Overall survival analyses were calculated using
Kaplan–Meier log-rank survival analysis, and 90-day mortalities
were excluded from analysis. A P-value of <0.05 was considered to
indicate statistical significance. Univariate andmultivariate binary
logistic regression analyses were used to evaluate risk factors for
postoperative HI. Clinically relevant preoperative factors signifi-
cant on univariate binary logistic regression analysis to a P-value
of <0.1 were included in the multivariate model. In cases of mul-
ticollinearity between covariates, the single factor that best
encompassed the clinical entity was selected for the model.
Results
Preoperative demographics, comorbidities and
operative indications
Patient demographics, comorbidities and pathologic characteris-
tics are shown in Table 1. No patient had encephalopathy. Patients
undergoing, respectively, RPS (n = 100) and RH (n = 480) were
similar in age, sex, race, comorbidities and American Society of
Anesthesiologists (ASA) risk score, and had similar preoperative
albumin and bilirubin levels and MELD scores (Table 1). Most
patients had a Child–Pugh score of 5 (n = 392, 67.6%) and the
majority were classified as Child–Pugh class A. More of the small
subset of patients classified as Child–Pugh class B underwent RPS
than RH (Table 1). No patients were classified as Child–Pugh
class C.
Of the 444 patients who underwent hepatic resection for malig-
nancy, 210 (47.3%) received neoadjuvant chemotherapy. The pro-
portions of patients receiving neoadjuvant chemotherapy did not
differ between operative groups (50.0% of the RPS group, 47.0%
of the RH group; P = 0.725). In patients who underwent resection
for malignancy, the five most common diagnoses were colorectal
liver metastases (CLM) (n = 256, 57.7%), hepatocellular carci-
noma (n = 65, 14.6%), cholangiocarcinoma (n = 36, 8.1%),metas-
tases from neuroendocrine tumours (n = 24, 5.4%) and breast
carcinoma (n = 11, 2.5%). Other diagnoses included metastatic
renal cell carcinoma (n = 8, 1.8%), adenocarcinoma not otherwise
specified (n = 7, 1.6%), sarcoma (n = 7, 1.6%), gastrointestinal
stromal tumours (n = 5, 1.1%), and other less commonmalignan-
cies (n = 25, 5.6% total, less than 1% each). There were no differ-
ences in the frequencies of the five most common histologic
diagnoses between patients with malignancy undergoing RPS
versus RH (P = 0.254).
In the 136 patients submitted to hepatic resection for benign
indications, the most common indication was haemangioma (n =
31, 22.8%), followed by adenoma (n = 22, 16.2%), focal nodular
hyperplasia (n = 17, 12.5%), abscess/infectious process (n = 12,
8.8%), cystic disease (n = 12, 8.8%), cholangitis (n = 8, 5.9%), and
haematoma (n = 7, 5.1%). Other indications included angiomy-
olipoma, arteriovenous malformation, biliary cystadenoma, cir-
rhotic nodule and hepatolithiasis (<5%).
Operative procedures and perioperative outcomes
Laparoscopic resection was possible in 57 patients (9.8%) and was
employed similarly in patients undergoing RPS and RH (Table 2).
Amongst patients undergoing RPS, the right hepatic vein was
resected in 52 patients (53.6%). Amongst patients undergoing
RH, the middle hepatic vein was resected in four patients (0.1%).
Additional surgical procedures were required in 110 patients
(19.0%), and involved hepatic procedures in 83 (75.5%), extrahe-
patic procedures in 24 (21.8%), and a combination of both in
three (2.7%) patients. The most common additional procedure
was hepatic wedge resection or anatomic segmentectomy (n = 36,
6.2% of all patients), followed by intraoperative ablation (n = 28,
4.8%). Bowel resection was performed in 14 patients (2.4%); the
incidence of bowel resection did not differ between the RPS and
RH groups (4.0% versus 2.1%; P = 0.278). Two patients required
distal pancreatectomy in addition to hepatic resection; one under-
went RH for metastatic colorectal cancer and required splenec-
tomy, and the other underwent RPS for metastatic pancreatic
neuroendocrine carcinoma. Other less frequent operations
included abdominal hernia repair, adrenalectomy, hepatic cyst
fenestration and nephrectomy (<1%). The frequency of addi-
tional surgical procedures did not differ by hepatic resection type
(20.0% in the RPS group and 18.8% in the RH group; P = 0.881).
Overall, 242 (41.7%) patients experienced complications and
87 (15.0%) experienced major complications. Reoperation was
required in 18 (3.1%) patients. A total of 28 (4.5%) patients died
during the 90-day postoperative period. Patients undergoing RPS
and RH had similar volumes of operative blood loss, transfusion
requirements, margin-positive resection rates, complication rates
and hospital lengths of stay (Table 2). Postoperative HI occurred
less frequently after RPS (Table 2). Of the 42 patients with HI, 26
(61.9%) had a postoperative bilirubin level of >7 mg/dl and an
additional 16 (38.1%) were considered to have HI based solely on
the presence of significant ascites. When the definition of HI was
narrowed to include only patients with a bilirubin level of >7 mg/
dl,23 all patients with HI were found to have undergone RH (n =
26, 4.5% of all patients; P = 0.013). Of the 42 patients with HI, six
(1.0% of the entire cohort) progressed to acute postoperative
hepatic failure; all had undergone RH (P = 0.596). Perioperative
mortality at 60 days and 90 days was higher in patients submitted
to RH than in those submitted to RPS, but the difference was not
statistically significant (Table 2).
The incidence of HI was higher in patients defined as being in
Child–Pugh class B preoperatively (six of 57, 10.5%); all six of
these patients met criteria for HI based on hyperbilirubinaemia.
Four of the six patients experienced an increase in bilirubin of
>10 mg/dl above baseline; only one had a preoperative bilirubin
level of >7 mg/dl.
The incidence of HI was higher in patients with malignancy
(n = 41, 9.3%) than in those undergoing resection for benign
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indications (n = 4, 2.9%) (P = 0.016). Preoperative factors signifi-
cantly associated with HI on univariate analysis are shown in
Table 3. In comparisonwith RPS,RH remained an independent risk
factor for the development of postoperative HI after controlling for
preoperative risk factors in all patients [hazard ratio (HR) = 9.628,
95% confidence interval (CI) 1.295–71.573; P = 0.027] (Table 3)
and in the subset of patients submitted to resection for malignancy
(HR = 9.662, 95% CI 1.288–72.450; P = 0.027) (Table 4).
Table 1 Clinicopathologic characteristics of patients submitted to, respectively, right posterior sectorectomy (RPS) and right hepatectomy
(RH)
Characteristic All patients (n = 580) RPS group (n = 100) RH group (n = 480) P-valuea
Age, years, median (range) 56.1 (20.3–87.8) Mean: 57.5 Mean: 54.7 0.073
Male gender, n (%) 252 (43.4%) 42 (42.0%) 210 (43.8%) 0.833
Race, n (%)
White 442 (76.2%) 78 (78.0%) 364 (75.8%) 0.874
Black 91 (15.7%) 15 (15.0%) 76 (15.8%)
Other 47 (8.1%) 7 (7.0%) 40 (8.3%)
ASA risk score, n (%)
1 52 (9.0%) 5 (5.0%) 47 (9.8%) 0.383
2 235 (40.5%) 46 (46.0%) 189 (39.5%)
3 272 (46.9%) 46 (46.0%) 226 (47.3%)
4 19 (3.3%) 3 (3.0%) 16 (3.3%)
Alcohol abuse, n (%) 38 (6.6%) 7 (7.0%) 31 (6.5%) 0.988
Smoking history, n (%) 116 (20.0%) 18 (18.0%) 98 (20.5%) 0.699
Diabetes mellitus, n (%) 78 (13.4%) 15 (15.0%) 63 (13.2%) 0.740
Hypertension, n (%) 222 (38.2%) 40 (40.0%) 182 (37.9%) 0.782
Hepatitis B, n (%) 20 (3.4%) 3 (3.0%) 17 (3.5%) 1.000
Hepatitis C, n (%) 21 (3.6%) 2 (2.0%) 19 (4.0%) 0.555
Ascites (preoperative), n (%) 4 (0.7%) 1 (1.0%) 3 (0.6%) 0.532
Preoperative laboratory values, median (range)
Platelets, ¥1000/mcl 237.5 (47–903) Mean: 238.8 Mean: 250.8 0.234
Albumin, g/dl 3.90 (1.1–5.0) Mean: 3.69 Mean: 3.75 0.396
Creatinine, mg/dl 0.90 (0.2–10.13) Mean: 0.88 Mean: 0.92 0.427
International normalized ratio (INR) 1.00 (0.7–2.1) Mean: 1.04 Mean: 1.02 0.058
Total bilirubin, mg/dl 0.60 (0.0–7.8) Mean: 0.65 Mean: 0.71 0.458
MELD score, median (range) 6.43 (6–28) Mean: 7.84 Mean: 7.65 0.488
Child–Pugh class, n (%)
A 523 (90.2%) 84 (84.0%) 439 (91.5%) 0.036
B 57 (9.8%) 16 (16.0%) 41 (8.5%)
Pathological characteristics
Malignancy (versus benign), n (%) 444 (76.6%) 77 (77.0%) 363 (75.6%) 0.870
Tumour size, cmb, median (range) 4.0 (0–25.0) Mean: 5.4 Mean: 5.9 0.376
Positive marginb, n (%) 49 (11.0%) 7 (9.1%) 42 (11.6%) 0.694
Cirrhosisc, n (%) 26 (4.5%) 7 (7.1%) 19 (4.0%) 0.274
Fibrosisc, n (%) 49 (8.4%) 4 (4.0%) 45 (9.4%) 0.110
Steatosisc, n (%) 168 (29.0%) 36 (36.4%) 132 (27.5%) 0.099
Steatohepatitisc, n (%) 7 (1.2%) 1 (1.0%) 6 (1.2%) 1.000
aP-value compares patients in the RPS group with patients in the RH group, a < 0.05. Comparisons for continuous variables were made using
Student's t-test; those for discrete variables were made using either Fisher's exact test or Pearson's chi-squared test. P-values in bold indicate
statistically significant differences (at P < 0.05).
bFor patients with malignancy only.
cSpecific pathologic characteristics unknown for one patient.
ASA, American Society of Anesthesiologists; MELD, Model for End-stage Liver Disease.
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Longterm outcomes: patients with malignancy
Postoperatively, 30 (30.0%) patients in the RPS group and 164
(34.2%) patients in the RH group received adjuvant chemo-
therapy (P = 0.479). Median follow-up in patients with malig-
nancy (n = 444) was 15.6 months (range: 0.0–150.9 months); 172
(38.7%) patients had died at the time of last follow-up. In patients
with CLM (the largest subgroup based on pathology), median
follow-up was 17.3 months (range: 0.0–130.5 months); there were
no significant differences in length of follow-up between patients
submitted to RPS and those submitted to RH (19.6 months versus
28.5 months; P = 0.133). Median overall survival was 54.1 months
(95% CI 41.5–66.7 months). Overall survival did not differ
between patients submitted to RPS and RH, respectively (Fig. 3).
Discussion
The purpose of this study was to compare the perioperative out-
comes of two methods of partial hepatectomy for right-sided
Table 2 Perioperative outcomes in patients after right posterior sectorectomy (RPS) and right hepatectomy (RH)
Characteristic RPS group (n = 100) RH group (n = 480) P-value
Laparoscopic approach, n (%) 13 (13.0%) 44 (9.2%) 0.324
Portal vein reconstruction, n (%) 0 1 (1.5%) 1.000
Caudate lobectomy, n (%) 0 11 (3.3%) 0.134
Estimated blood loss, ml, mean 697.4 713.5 0.900
Perioperative transfusion, n (%) 19 (19.2%) 82 (17.1%) 0.720
Number of units transfuseda, mean 4.74 4.23 0.796
Postoperative peak total bilirubin, mg/dl, mean 1.64 3.03 <0.0001
Postoperative peak INR, mean 1.22 1.46 <0.0001
Complication, n (%) 42 (42.0%) 200 (41.8%) 1.000
Major complication (Grades III–V), n (%) 15 (15.0%) 72 (15.0%) 1.000
Infectious complication, n (%) 19 (19.0%) 74 (15.4%) 0.460
Bile leak, n (%) 3 (3.0%) 19 (4.0%) 1.000
Ascites (postoperative), n (%) 1 (1.0%) 19 (4.0%) 0.225
Reoperation, n (%) 3 (3.0%) 15 (3.1%) 1.000
Hepatic insufficiencyb, n (%) 1 (1.0%) 41 (8.5%) 0.005
Length of stay, days, mean 7.5 8.3 0.360
60-day mortality, n (%) 2 (2.0%) 22 (4.6%) 0.404
90-day mortality, n (%) 3 (3.0%) 25 (5.2%) 0.449
aOf the patients receiving transfusion.
bDefined as postoperative bilirubin >7 mg/dl or presence of significant postoperative ascites.
P-values in bold indicate statistically significant differences (at P < 0.05).
INR, international normalized ratio.
Table 3 Multivariate analysis of preoperative risk factors for postoperative hepatic insufficiency in all patients (n = 580)
Risk factor Univariate Multivariate
P-value HR 95% CI P-value
Decreased plateletsa 0.023 – – –
Increased total bilirubina <0.0001 – – –
Male sex 0.014 1.883 0.954–3.715 0.068
Hepatitis C 0.006 3.433 1.130–10.433 0.030
Malignancy 0.017 3.601 1.061–12.223 0.040
Increasing MELD score 0.004 1.119 1.021–1.226 0.016
Perioperative blood transfusion 0.020 2.220 1.061–4.647 0.034
RH (versus RPS) 0.030 9.628 1.295–71.573 0.027
aExcluded from multivariate model as a result of multicollinearity with MELD score.
P-values in bold indicate statistically significant differences (at P < 0.05).
HR, hazard ratio; 95% CI, 95% confidence interval; MELD, Model for End-stage Liver Disease; RH, right hepatectomy; RPS right posterior
sectorectomy.
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pathology: formal RH (segments V–VIII), and RPS (segments VI
and VII). For lesions located in the posterior sector, either RPS or
formal RH may be performed. The posterior location and relative
sizes of segments VI and VII make RPS technically challenging;
some surgeons view the lengthy parenchymal resection as a poten-
tial cause of morbidity, the risk for which must be weighed against
the value of parenchymal preservation. Although others have
documented successful series of patients submitted to RPS,14,19,31–33
this retrospective analysis is the first to focus on differences in
perioperative outcomes between patients undergoing RPS and
RH, respectively.
Adequate parenchymal preservation is particularly important
in view of the aggressive surgical approach employed today for
the treatment of primary liver cancers and hepatic metastases.
Advances in chemotherapeutic and targeted agents mean that
hepatic resection is pursued frequently in patients who historically
would have been considered unresectable. Other patients with
favourable disease biology show extended survival with repeat
hepatectomy.4,6,16 In one of the largest series of major hepatic
resections to be reported, Jarnagin et al.1 described one or more
repeat hepatectomies in 85 of 1568 (5.4%) patients who under-
went surgery during 1991–2001. A recent large series (n = 2628)
reported from the MD Anderson Cancer Center (MDACC) cited
an increase in the frequency of repeat hepatectomy from 6.1% to
12.2% (P = 0.02) between 1997 and 2011.34 Another series
restricted to patients undergoing repeat hepatectomy for CLM
(n = 246) demonstrated that significant proportions of well-
selected patients may go on to require third (18.7%) and fourth
(3.7%) hepatectomies.17 With continued improvements in
medical therapy and changes in surgical approaches over time, the
rate of re-resection of hepatic metastases can be expected to
increase. Because the current study was designed to assess periop-
erative outcomes, specific longterm data on recurrence and sub-
sequent repeat hepatic resection were unavailable. In theory,
patients undergoing RPS, with the resultant preservation of the
parenchyma and right portal structures, are more likely to have
sufficient functional hepatic volume to allow for aggressive repeat
resections when oncologically appropriate. The clinical character-
istics, perioperative morbidity and mortality, and oncologic
outcomes of patients requiring repeat resection should be
Table 4 Multivariate analysis of preoperative risk factors for postoperative hepatic insufficiency in patients with malignancy (n = 444)
Risk factor Univariate Multivariate
P-value HR 95% CI P-value
Decreased plateletsa 0.029 – – –
Increased total bilirubina <0.0001 – – –
Neoadjuvant chemotherapy 0.050 0.719 0.344–1.503 0.381
Male sex 0.055 1.918 0.942–3.902 0.073
Increasing ASA score 0.087 1.287 0.761–2.174 0.346
Hepatitis C 0.012 3.061 0.965–9.709 0.058
Increasing MELD score 0.002 1.117 1.015–1.228 0.024
Perioperative blood transfusion 0.055 2.030 0.932–4.420 0.075
RH (versus RPS) 0.031 9.662 1.288–72.450 0.027
aExcluded from multivariate model as a result of multicollinearity with MELD score.
P-values in bold indicate statistically significant differences (at P < 0.05).
HR, hazard ratio; 95% CI, 95% confidence interval; ASA, American Society of Anesthesiologists risk score; MELD, Model for End-stage Liver Disease;
RH, right hepatectomy; RPS right posterior sectorectomy.
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Figure 3 Overall survival in patients with colorectal liver metastases
undergoing right posterior sectorectomy (RPS) and right hepatec-
tomy (RH), respectively (P = 0.642). Survival is truncated at
65 months, when the number at risk does not exceed five
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characterized in future studies focused on a single disease type.
Regardless, the potential rate of repeat hepatectomy underlines
the importance of parenchymal preservation in the initial
operation.
Despite the advantage of parenchymal preservation, there are
multiple reasons for pursuing RH rather than RPS. The technical
difficulty of RPS is greater than that of RH and differences in the
surgeon’s level of comfort with the operation and intraoperative
ultrasound are potential factors that are difficult to capture in a
retrospective study. Other factors that may influence the operative
approach and are also not captured in this study include differ-
ences in cost and reimbursement between the two procedures
(which have unique ICD-9 codes and financial implications).
Financial cost should never determine any oncologic procedure,
but consideration of costs may be reasonable if two procedures are
deemed equivalent in all other aspects.Although the current study
suggests that RPS is similar to RH in terms of morbidity, conclu-
sions on the equivalence of the two procedures are limited by the
study’s retrospective nature and the lack of data on longterm
oncologic outcomes.
A more measurable factor that may cause some to favour RH
over RPS refers to increases in operative blood loss and/or bile leak
associated with the longer transection distance required in RPS.
However, in this study RPS was not associated with significantly
different rates of blood loss, transfusion or bile leak. Patients
submitted to RPS were similar to those submitted to RH in terms
of demographics, preoperative comorbidities and operative indi-
cations. Patients submitted to RPS had a significantly lower rate of
postoperative HI than those submitted to RH, which is probably
attributable to greater parenchymal preservation. The preserva-
tion of functional parenchyma is well documented as a predictive
factor for decreased morbidity and mortality, both overall and
liver-related.1,2,35 Overall, morbidity rates in both operative groups
were similar, which suggests that RPS is comparable with RH in
appropriately selected patients, and may be advantageous in terms
of parenchymal preservation.
The incidence of HI in this study is within the ranges reported
previously,35–39 but is higher than that cited in a recent large series
of major hepatic resections from MDACC (2.6–3.1%).34 Direct
comparisons between institutions of rates of HI are made difficult
by variations in extents of resection and definitions of HI.23,36,37,40
The International Study Group of Liver Surgery defines HI as:
‘. . . impaired ability of the liver to maintain its synthetic, excre-
tory, and detoxifying functions, which are characterized by an
increased international normalized ratio (INR) and concomitant
hyperbilirubinaemia.’37 Using the INR as a measure for HI has
limitations because it is influenced by exogenous vitamin K
administration or by the transfusion of clotting factors such as
fresh frozen plasma. Postoperative bilirubin of >7 mg/dl has been
proposed by others as a simplified and standardized definition
and was the strongest predictor of morbidity and mortality (all-
cause and liver-related) after major hepatic resection in a multi-
institution series of 1059 patients.23 In the recent MDACC study,34
HI was defined as postoperative bilirubin >7 mg/dl. The current
study used the same definition of hyperbilirubinaemia, but also
used the presence of significant ascites24 as a surrogate criterion
for hepatic dysfunction, which accounted for slightly more than
one-third of the diagnoses of HI. When HI was defined only by a
bilirubin level of >7 mg/dl, its rate in the current study decreased
to 4.5% and occurred only in patients who had undergone RH.
Operation type (RH) remained significantly associated with
increased risk for HI after other preoperative risk factors were
accounted for, including male gender35,40 and presence of diabetes
mellitus35 and/or hepatitis C.40Another potential contributor toHI
that has been less consistently documented is receipt of neoadju-
vant therapy.35,40 In the current study, neoadjuvant therapy was not
significantly associated with HI, which mirrors findings in other
studies.7,38 It is likely that simple receipt of therapy is not an
accurate predictor of chemotherapy-induced liver injury,41 but
given the heterogeneity of chemotherapy regimens utilized within
the diverse study population, the accurate quantification of specific
regimens anddurationof therapywas not possible.The presence of
underlying liver disease, such as steatosis, is associated with an
increased incidence of complications aftermajor hepatectomy and
parenchymal preservation may be particularly beneficial in such
patients.31,38,42 In heavily pretreated populations with a high fre-
quency of chemotherapy-induced liver injury and in patients with
a higher incidence of underlying liver disease, the parenchymal
preservation afforded by RPS may be particularly beneficial.
The present study has several limitations. It was not possible to
review preoperative radiographic studies because procedures for
storing radiographic studies changed over time at each institution
and a large percentage of patients had obtained preoperative
radiographic studies at outside facilities. Thus it was not possible
to identify patients who underwent RH but would have been
suitable candidates for RPS; this represents a major limitation of
this retrospective study. However, it is the authors’ opinion that a
prospective randomized controlled trial comparing RPS with RH
is unlikely to accrue. The study is also limited by its inability to
accurately identify the percentage of patients requiring a Pringle
manoeuvre or the duration of the manoeuvre, which may have
important implications on the development of postoperative HI.
Finally, although the present data allow an initial evaluation of
longterm survival in patients with CLM, the oncologic non-
inferiority of RPS in this heterogeneous group of patients cannot
be fully evaluated. Future studies examining longterm outcomes
in more homogeneous patient populations matched for tumour
size and location are required.
The current, large, dual-institution study demonstrates that
patients undergoing RPS and RH, respectively, experience similar
rates of blood loss and overall morbidity (including bile leak), but
that patients submitted to RPS experience significantly less post-
operative HI. Right posterior sectorectomy is parenchyma-sparing
and should be considered when it is technically feasible and onco-
logically sound in patients with disease of the right posterior
sector.
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